- Home
- XTKG vs NRSN Comparison
XTKG vs NRSN Comparison
Compare XTKG & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTKG
- NRSN
- Stock Information
- Founded
- XTKG 1997
- NRSN 2017
- Country
- XTKG Singapore
- NRSN Israel
- Employees
- XTKG 178
- NRSN N/A
- Industry
- XTKG
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- XTKG
- NRSN Health Care
- Exchange
- XTKG NYSE
- NRSN Nasdaq
- Market Cap
- XTKG 13.7M
- NRSN 17.8M
- IPO Year
- XTKG 2019
- NRSN 2021
- Fundamental
- Price
- XTKG $0.99
- NRSN $1.09
- Analyst Decision
- XTKG
- NRSN Hold
- Analyst Count
- XTKG 0
- NRSN 1
- Target Price
- XTKG N/A
- NRSN N/A
- AVG Volume (30 Days)
- XTKG 205.7K
- NRSN 374.5K
- Earning Date
- XTKG 11-27-2024
- NRSN 12-18-2024
- Dividend Yield
- XTKG N/A
- NRSN N/A
- EPS Growth
- XTKG N/A
- NRSN N/A
- EPS
- XTKG N/A
- NRSN N/A
- Revenue
- XTKG $15,234,138.00
- NRSN N/A
- Revenue This Year
- XTKG N/A
- NRSN N/A
- Revenue Next Year
- XTKG N/A
- NRSN N/A
- P/E Ratio
- XTKG N/A
- NRSN N/A
- Revenue Growth
- XTKG 51.59
- NRSN N/A
- 52 Week Low
- XTKG $0.08
- NRSN $0.51
- 52 Week High
- XTKG $2.14
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- XTKG 49.71
- NRSN 47.35
- Support Level
- XTKG $0.90
- NRSN $1.01
- Resistance Level
- XTKG $1.38
- NRSN $1.13
- Average True Range (ATR)
- XTKG 0.17
- NRSN 0.09
- MACD
- XTKG -0.02
- NRSN -0.01
- Stochastic Oscillator
- XTKG 23.92
- NRSN 27.27
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries that operates across four business segments: digital technologies, renewable energy, Cryptomining Operations, and agriculture technologies.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.